ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0570

BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: PP04

Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 0225

Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0462

Breastfeeding Intention in Systemic Lupus Erythematosus Patients

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0504

Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0308

Burden of Osteoarthritis Attributable to High BMI in 38 OECD Countries: A Benchmarking Analysis

(0308–0324) Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0135

Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0143

Cancer Incidence in Familial Mediterranean Fever

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0607

CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0448

Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0467

Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0051

CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0004

CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation

(0001–0008) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

«Previous Page
1
…
6
7
8
9
10
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.